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1. Introduction
Lack of potent drug and gene delivery is one of the major problems of cancer chemotherapy
and biotherapy. Different non-viral approaches have been proposed for drug and gene
delivery such as physical and chemical methods. Physical delivery systems are one of the
efficient non-viral methods including electroporation, micro-injection, gene gun, tattooing,
laser and ultrasound [Bolhassani and Rafati, 2011]. Electroporation (EP) is the formation of
aqueous pores in lipid bilayers by the application of a short (microseconds to milliseconds)
high-voltage pulse to overcome the barrier of the cell membrane. This transient, permeabilized
state can be used to load cells with a variety of different molecules including ions, drugs, dyes,
tracers, antibodies, oligonucleotides, RNA and DNA [Faurie et al., 2005]. Electroporation has
proven useful both in vitro, in vivo and in patients, where drug delivery to malignant tumors
has been performed. In addition, the data show that electroporation of DNA vaccines in vivo
is an effective method to increase cellular uptake of DNA and gene expression in tissue leading
to marked improvement in immune responses. Electroporation represents a way of increasing
the number of DNA-transfected cells and enhancing the magnitude of gene expression, while
reducing intersubject variability and requiring less time to reach a maximal immune response
compared to conventional intramuscular injection of the vaccine [Monie et al., 2010].
Delivery of DNA vaccines using electroporation has already been tested successfully in a wide
range of disease models. Electroporation has been used to enhance immune responses using
DNA vaccines directed against infectious diseases such as influenza, HIV, hepatitis C, malaria,
anthrax or to treat or prevent the development of tumors including breast cancer, prostate
cancer and melanoma [Daemi et al., 2012; Best et al., 2009]. The studies have shown that in
vivo EP mediated vaccination is a safe and effective modality for the treatment of prostate
cancer and has potential to be used as a neo-adjuvant or adjuvant therapy [Ahmad et al.,
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2010]. Electroporation has been successfully used to administer HPV DNA vaccine to mice as
well as rhesus macaques, which has prompted its use in an ongoing phase I clinical trial such
as VGX-3100, a vaccine that includes plasmids targeting E6 and E7 proteins of both HPV
subtypes 16 and 18, for treatment of patients with CIN 2 or 3. In addition, electroporation has
been used as an effective vaccination technique for the treatment of HPV induced cancers using
the pNGVL4a-CRT/E7 (detox) DNA vaccine [Monie et al., 2010]. The application of in vivo
electroporation to the sites receiving injected plasmid DNA has allowed for dramatic increases
in immune responses compared with plasmid DNA injection alone. Among the tissues
targeted for in vivo electroporation have been skin, liver, tumors and muscle [Widera et al.,
2000]. Regarding to in vivo EP is predominantly carried out intramuscularly (i.m.), currently,
skin EP is used as an attractive and less invasive option that is able to induce robust adaptive
immune responses. To date, studies of DNA EP in skin have mainly focused on antigen
expression, antigen specific humoral immunity, induction of IFN-γ-producing T cells and
protective efficacy to infection [Daemi et al., 2012; Brave et al., 2011]. Plasmid DNA vaccination
using skin electroporation (EP) is a promising method able to elicit robust humoral and CD8+T-
cell immune responses while limiting invasiveness of delivery [Brave et al., 2011].
However, this method sometimes leads to cell death, primarily when the electrical fields cause
permanent permeabilization of the membrane and the consequent loss of cell homeostasis, in
a process known as irreversible electroporation [Rubinsky, 2007]. This is an unusual mode of
cell death that is not understood yet. The electroporation procedures used in many laboratories
could be optimized with limited effort. Moreover, electroporation, used alone or in combina‐
tion with other enhancement methods, expands the range of drugs (small to macromolecules,
lipophilic or hydrophilic, charged or neutral molecules) that can be delivered transdermally
[Escobar-Chávez et al., 2009; Denet et al., 2004]. The efficacy of transport depends on the
electrical parameters and the physicochemical properties of drugs. The in vivo application of
high-voltage pulses is well tolerated, but muscle contractions are usually induced. The
electrode and patch design is an important issue to reduce the discomfort of the electrical
treatment in humans [Denet et al., 2004]. It was shown that poloxamer 188, added before or
immediately after an electrical pulse used for electroporation decreases the number of dead
cells and at the same time does not reduce the number of reversible electropores through which
small molecules (cisplatin, bleomycin, or propidium iodide) can diffuse. It was suggested that
hydrophobic sections of poloxamer 188 molecules are incorporated into the edges of pores and
that their hydrophilic parts act as brushy pore structures. The formation of brushy pores may
reduce the expansion of pores and delay the irreversible electropermeability. These techniques
show a potential for drug and gene delivery. However, site-specific and efficient delivery still
remains a difficult problem [Tsoneva et al., 2010]. The voltages generally used for electropo‐
ration in animals range from 100 to 1200 V/cm. The investigators have shown that low-voltage
electroporation can induce immunity and protect mice effectively [Daemi et al., 2012; Zhou et
al., 2008]. In addition, intradermal DNA electroporation is one of the most efficient non-viral
methods for the delivery of gene into the skin [Lin et al., 2012]. Previous studies have demon‐
strated that a combination of a short high voltage pulse (HV) and a long duration low-voltage
pulse (LV) was efficient for DNA electroporation in the skin and that intradermal electropo‐
ration was suitable to deliver DNA vaccine when a Th1-oriented response is desired [Pavselj
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and Préat, 2005]. Various cell types of the skin are involved in the development of immune
response. Langerhans cells (LC) due to their long dendritics and their horizontal orientation,
create an almost continuous network that enables them to capture most antigens that enter
through the skin. Delivery of DNA into the skin could induce direct-presentation of the
encoded antigen by APC or cross-presentation after uptake by keratinocytes. Some studies
have indicated that EP induces IgG and Th-cell responses higher than Intramuscular (IM)
delivery [Lee et al., 2011]. This chapter is further focused on the use of electroporation-induced
delivery of anti-cancer drugs, gene and vaccines in human cancer cells along with description
of its advantages and disadvantages.
2. Non-viral delivery systems
Generally, the methods of delivering a gene, vaccine and drug are divided into: a) Physical/
non-viral approaches such as tattooing, gene gun, ultrasound, electroporation, laser; b)
Chemical/ non-viral systems such as: cationic lipids/liposomes, polysaccharides, cationic
polymers, cationic peptides, micro-/ nano-particles and c) Biological/ viral vectors [Bolhassani
et al., 2011]. Non-viral vectors are safe in human body and easy for use. Among them,
electroporation can be used to distribute nucleic acid fragments, oligonucleotides, siRNA and
plasmids to cells. Studies using electroporation were performed in vivo; however electropo‐
ration is sometimes harmful to differentiated adult cells [Anwer, 2011; Wang et al., 2012]. Non-
viral vectors are attractive tools in gene therapy and vaccine delivery [Draghia-Akli et al., 2005].
3. History and definition of electroporation
Electroporation was introduced in the 1960s and comprises the application of controlled
electric fields to facilitate cell permeabilization. The success of in vitro delivery by electropo‐
ration has led to the development of in vivo applications [Takei et al., 2008]. The first in vitro
and in vivo attempts to use electroporation in gene transfer were demonstrated in 1982 and
1991, respectively [Al-Dosari and Gao, 2009]. In vivo electroporation depends on electric pulses
to drive gene transfer. These pulses generated transient pores in cell membranes followed by
intracellular electrophoretic DNA movement. Typically, in vivo electroporation is performed
by first injecting DNA to the target tissue followed by electric pulses, with varied voltage, pulse
duration and number of cycles, from two applied electrodes [Al-Dosari and Gao, 2009, Hao et
al., 2012]. This technique is generally safe, efficient and can produce good reproducibility
compared to other non-viral methods. When its parameters are optimized, this method can
generate transfection efficiency equal to that in viral vectors [Al-Dosari and Gao, 2009]. The
initial study of in vivo EP was the delivery of chemotherapeutic agents to solid tumors. In the
mid-to late 1990s, the efficacy of this approach for drug delivery was demonstrated in a variety
of different animal and human tumors. This technique was then tested for enhanced plasmid
DNA delivery and subsequently, the initiation of the first clinical trials [Heller and Heller,
2006]. Furthermore, the expression of reporter genes was used to optimize in vivo EP param‐
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eters, to explore the mechanism of EP and to show delivery in a new tissue. The use of in
vivo EP for gene delivery including immune modulators, cell cycle regulators, suicide genes,
anti-angiogenic genes and genes encoding toxins has established its potential for many
therapeutic applications [Heller and Heller, 2006]. In vivo electroporation as compared to other
gene transfer methods, such as viral vectors, has several advantages: a) various types of DNA
constructs (or RNAi vectors) are readily introduced to the cells without limitation of DNA size;
b) more than two different DNA constructs can be introduced into the same cells [Matsuda
and Cepko, 2007]. Altogether, delivery by electroporation has been performed to a number of
tissues including skin, muscle, liver, testes and tumors employing a wide range of electrical
conditions and electrodes. While this preclinical research is promising, further optimization
of electrical conditions and electrodes would be necessary for clinical use [Fioretti et al., 2013;
Heller and Lucas, 2000].
4. Electroporation mechanisms
The development of theoretical models has developed our understanding of electroporation
mechanism. Electropermeabilization of cells mainly involves the interaction of the electric field
with the lipid domains of the cell membrane. Experimentally measured quantities consist of
the membrane lifetimes, the current, the membrane conductance and transmembrane voltage.
Regarding to the accumulated evidence, the pores are formed because of the electric field. The
transient aqueous pore theory describes the main features of electropermeabilization, which
is one major consequence of electroporation. Molecular transport of charged molecules
appears to be predominantly due to electrical flow through pores, such that the elevated
transmembrane voltage plays two roles: (a) creation of pores and (b) provision of a local driving
force [Weaver and Chizmadzhev, 1996]. Electrochemotherapy (ECT) is a cancer therapy that
conjugates the administration of a chemotherapy agent to the delivery of permeabilizing pulses
released singularly or as bursts. This approach results in higher number of anticancer mole‐
cules delivered to their biological targets, but is also associated to undesirable side effects such
as pain and muscular spasms. A new electroporator delivering eight biphasic pulses at the
voltage of 1,300 V/cm lasting + 50 µsec each, with a frequency of 1 Hz, and with 10-µsec
interpulse intervals (total treatment time: 870 µsec/cm2 of treated area) was tested on the
human lung cancer cell line (A549) and both in mice xenografts and rabbits with spontaneous
tumors. The tumor cell line treated with electroporation showed efficient drug delivery
suggesting further cell death. In addition, in vivo data demonstrated that the new permeabi‐
lizing protocol adopting biphasic electric pulses displays a significant higher efficacy com‐
pared to previous ECT treatments and consequently, substantial reduction of the morbidity
[Spugnini et al., 2014].
5. Applications of electroporation
Skin electroporation could be particularly appropriate for topical drug delivery. Skin electro‐
poration temporarily permeabilizes the barrier to drug permeation and therefore could
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broaden topical delivery to drugs not suitable for delivery by passive diffusion (i.e., hydro‐
philic, charged, and/or large molecular drugs). The use of high-voltage pulses could also
enhance the permeability of viable cells as demonstrated by the electrochemotherapy of tumors
(e.g., bleomycin) or DNA transfection [Escobar-Chávez et al., 2009]. Indeed, the application of
electrical pulses to a cell creates a transient permeability that allows entry of hydrophilic
molecules such as drugs and plasmid DNA. The exact mechanism by which the plasmid enters
the cell following electroporation is unclear. Although, small molecules such as drugs can enter
cells via transient pores, it seems that macromolecules such as plasmid DNA enter by a more
complex interaction with the cell membrane. This interaction is enhanced by the application
of repeated pulses that brings the plasmid into closer contact with the cell membrane. The
voltage required for electroporation varies considerably and is dependent on cell size and
shape [Wells, 2010]. It ranges from values of approximately 100 V/cm in large cells up to 1-2
kV/cm in small cells such as bacteria. Plasmid electrotransfer is a multistep process from
interaction with the cell membrane, movement into the cell, intracellular trafficking and
passage across the nuclear membrane [Wells, 2010; Nakamura and Funahashi, 2013]. A variety
of different electrodes could be used depending on the cells to be treated. For in vitro studies,
electrode patterns vary from a cuvette figure for cells in suspension to complex electrode arrays
for adherent cells. An equal variety of electrodes have been developed for in vivo use, based
on the nature of the tissue being treated [Wells, 2010]. A wide range of pulse patterns have
been used both in vitro and in vivo. Repeated pulses appear better than single pulses. Some
authors suggest a combination of one high-voltage pulse with a series of low-voltage pulses.
Pulse magnitude and duration also has an effect on the damage caused to the cells. Pre-
treatment of skeletal muscle in vivo with hyaluronidase allows the use of a decreased voltage
and so reduces damage while maintaining efficiency. Plasmid size has a significant effect on
the efficiency of electroporation with a decreasing efficiency observed with increasing plasmid
size using the same expression cassette [Wells, 2010]. The in vitro and in vivo studies using
electroporation have been further described as following:
a. In vitro electroporation: Electroporation can be used to transfer a range of genetic materials
into cells including DNA, RNA and oligonucleotides. In addition, in vitro electroporation
is useful for synthetic oligonucleotides which have an uncharged backbone such as the
phosphorodiamidate morpholino oligomers [Wells, 2010]. The effects of electrical
treatment with high field intensity (200-1000 V/cm) were evaluated on two breast cancer
cells (MDA-MB-231 and MCF-7) and one fibroblast cell line 3T3. The degree of electro‐
permeabilization of the adherent cells elevated steadily with the increasing of the field
intensity. Furthermore, cell replication of both cancer cell lines was disturbed after
electropermeabilization. Altogether, the use of suitable electric pulses could trigger
changes in the cytoskeleton organization and cell adhesiveness, led to the enhancement
of anti-tumor effects [Pehlivanova et al., 2012].
b. In vivo electroporation: In vivo electroporation has been shown to be effective for a wide
range of tissues, including tumors, skin, liver, lung, kidney, thymus, bladder, adipose
tissue, vasculature, retina, cornea, ciliary muscle, brain, spinal cord, skeletal muscle and
testis, for delivering a range of genetic material such as DNA, RNA and oligonucleotides
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(e.g. siRNA, antisense oligonucleotides). In vivo plasmid electroporation has also been
used as either a primary or booster vaccination strategy that enhances cell-mediated
immune responses. Most of the studies using electroporation have involved local delivery
into the target organ but a few have studied local electroporation following systemic
(intravenous) delivery of the plasmid. For example, local electroporation targeted plasmid
delivery to the liver was effective for liver, kidney and spleen but was not successful for
skeletal muscle or skin [Wells, 2010]. Taken together, electroporation has been applied to
efficient delivery of drugs, genes and vaccines as described below. Figure 1 shows
common application of electroporation.
Figure 1. Common applications of electroporation
5.1. Drug delivery
Several studies have investigated the use of electroporation to enhance the efficacy of the drugs
especially used for the treatment of various cancer types. Current electroporation protocols
are based on preclinical studies. The authors reported the use of 1,000 V/cm (voltage/electrode
distance ratio) up to approximately 1,300 V/ cm for electrochemotherapy. One simple way of
lowering the applied voltage was to decrease the gap between electrodes, e.g., 0.4 cm [Gehl,
2008]. The threshold potential for transient electric breakdown of cell membranes is about 0.5
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V. For a cell with a 10 µm diameter, the field strength needed to reach and exceed a potential
of 0.5 V at each end is about 1,000 V/cm [Hui, 2013].
Transdermal drug delivery offers an attractive alternative to the conventional drug delivery
methods of oral administration and injection [Escobar-Chávez et al., 2009]. The subcutaneous
layer forms the major barrier to most water-soluble and many hydrophobic drugs and
contributes the major portion of the electric resistance of the skin. Electroporation is one of the
approaches to improve the transdermal delivery by transiently permeabilizing the skin to
facilitate drug transport. Transdermal drug delivery has several potential advantages over
other parenteral delivery methods. Apart from the convenience and non-invasiveness, the skin
also provides a “reservoir” that sustains delivery over a period of days [Hui, 2013]. The authors
have shown that if the voltage of the pulses exceeds a voltage threshold at 75–100 V (equivalent
to the breakdown threshold of 8–10 lipid bilayers in the SC), microchannels or “local transport
regions” are created through the breakdown sites of the SC [Hui, 2013]. Many small-molecule
drugs have been successfully delivered through the skin by electroporation. Transport
efficiency for small charged molecules (MW ≤ 1000, e.g., protoporphyrin IX), using the same
polarity pulses, was higher than that for uncharged molecules (e.g., protoporphyrin IX methyl
ester) or charged molecules with opposite polarity pulses. The results indicated that, besides
passive diffusion through electropores, electrophoretic force of the pulses also contributes to
the electroporation-enhanced transport of these charged molecules [Hui, 2013]. Therefore, the
efficacy of transport depends on the electrical parameters and the physicochemical properties
of drugs. Some studies indicated that the in vivo application of high-voltage pulses is well
tolerated, but muscle contractions are generally induced. Furthermore, the electrode and patch
design is an important issue to reduce the discomfort of the electrical treatment in humans
[Escobar-Chávez et al., 2009]. The electroporation has been first used to enhance the delivery
of chemotherapeutic drugs like cisplatin and bleomycin in cancer cells and solid tumors,
respectively. This application has been termed electrochemotherapy [Tsoneva et al., 2007;
Gehl, 2008].
5.1.1. Anti-cancer drugs
Electrochemotherapy, via cell membrane permeabilizing electric pulses, potentiates the
cytotoxicity of non-permeant or poorly permeant anticancer drugs with high intrinsic cyto‐
toxicity, such as bleomycin or cisplatin, at the site of electric pulse. Its advantages are high
efficacy on tumors with different histologies, simple application, minimal side effects and the
possibility of effective repetitive treatment. In clinical studies, electrochemotherapy has
proved to be a highly efficient and safe approach for treating cutaneous and subcutaneous
tumor nodules. The treatment response for various tumors (predominantly melanoma) was
approximately 75% complete and 10% partial response of the treated nodules [Escobar-Chávez
et al., 2009].
5.1.1.1. Bleomycin
A consistent finding is that lipo-or amphiphilic drugs traverse the cell membrane without
electroporation, while an enhancement in cytotoxicity is found with drugs that, under normal
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circumstances, do not pass the cell membrane easily. The most prominent example is bleo‐
mycin, which is a well-known drug. One bleomycin molecule can cause several DNA strand
breaks and is highly toxic inside the cell [Gehl, 2008]. Drug doses used in bleomycin-based
electrochemotherapy have been variable. Some groups have used intratumoral injection with
relatively high doses, while others have applied its lower doses. Also, for i.v. administration,
bleomycin is generally given in the doses used in standard treatment protocols. The results of
the different regimens are comparable, but there may be more necrosis with the higher doses
and a better chance to conserve normal tissue with the lower doses [Gehl, 2008]. In bleomycin
chemotherapy, treatment was more than 1000 times more effective with electroporation than
without electroporation. In comparison with bleomycin, other drugs such as daunorubicin,
doxorubincin, 5-fluorouracil and paclitaxel had no electroporation benefits [Hui, 2008].
Bleomycin electrochemotherapy has been successfully applied to treat melanomas, head and
neck squamous cell carcinomas, Kaposi’s sarcomas, as well as lung, breast, kidney, and bladder
cancers. Its cytotoxicity is higher in cancer tissues than in normal tissues, including arteries
and nerves. In certain stage II and III clinical trials, 100% complete recovery has been reported.
Bleomycin electrochemotherapy induces temporary vasoconstriction, which helps to retain
the drug in the tumor tissue [Hui, 2008].
As described above, the bleomycin is used with electroporation (electrochemotherapy) for
treatment of tumors in the clinical setting. Calcium electroporation offers several advantages
over standard treatment options: calcium is inexpensive and may readily be applied without
special precautions mentioned about cytostatic drugs. Therefore, details on the use of calcium
electroporation are essential for carrying out clinical trials comparing electrochemotherapy
[Frandsen et al., 2014]. Calcium electroporation can induce ATP depletion-associated cellular
death. The effects of calcium and bleomycin electroporation (alone or in combination) were
compared in three different cell lines (DC-3F, transformed Chinese hamster lung fibroblast;
K-562, human leukemia; and murine Lewis Lung Carcinoma) [Frandsen et al., 2014]. Further‐
more, the effects of electrical pulsing parameters and calcium compounds on treatment efficacy
were determined. The results showed that electroporation with either calcium or bleomycin
significantly reduced cell survival, without a synergistic effect at similar voltage parameters.
At equimolar concentrations, calcium chloride and calcium glubionate resulted in comparable
decreases in cell viability. Indeed, the effect of calcium electroporation is independent of
calcium compound [Frandsen et al., 2014]. Briefly, the calcium electroporation can be sug‐
gested as a potential cancer therapy in future clinical trial.
5.1.1.2. Poloxamer 188
Poloxamer 188, added before or immediately after an electrical pulse, decreased the number
of dead cells as well as it did not reduce the number of reversible electropores. It was suggested
that hydrophobic sections of poloxamer 188 molecules are incorporated into the edges of pores
and their hydrophilic parts act as brushy pore structures. The formation of brushy pores may
reduce the expansion of pores and delay the irreversible electropermeability. Its advantage is
the increased uptake and accumulation into reversibly electroporated tumor cells [Tsoneva et
al., 2010].
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5.1.2. Analgesic and anti-inflammatory drugs
Electroporation increased the permeation of h-cyclodextrin (BCD) and hydroxy propyl h-
cyclodextrin (HPCD), relative to passive transport. The presence of BCD and HPCD enhanced
the total transport of the permeants piroxicam and carboxyfluorescein (CF), respectively, from
both permeant solutions and suspensions. Another studies demonstrated that electroporation
may enhance and control transdermal permeation of nalbuphine (NA) and its prodrugs
including nalbuphine benzoate (NAB) and sebacoyl dinalbuphine ester (SDN). The results
indicated that the use of iontophoresis or electroporation significantly enhanced the in vitro
permeation of NA and its prodrugs. In addition, lipophilicity and molecular size had signifi‐
cant effects on skin permeation of NA, NAB, and SDN via passive diffusion or under the
electric field. The permeation amounts of NA and its prodrugs may be increased by application
of higher pulse voltage, pulse duration and pulse number [Escobar-Chávez et al., 2009].
5.1.3. Anti-diuretic drugs
Macromolecules were investigated as chemical enhancers of transdermal transport by skin
electroporation. Skin electroporation increased transdermal mannitol delivery [Escobar-
Chávez et al., 2009].
5.1.4. Anti-viral drugs
The use of electroporation pulses enhancing the skin permeability to deliver anti-viral drugs
is in the early stages of development. A systematic study examining the parameters influencing
electroporative transdermal delivery of terazosin hydrochloride to rat skin was previously
reported. It was found that voltage, pulse length and number of pulses were the three most
important parameters [Escobar-Chávez et al., 2009].
5.1.5. Beta-blocker agents
The studies have shown the effects of electroporation on iontophoretic transport of 2 beta-
blockers, timolol (lipophilic) and atenolol (hydrophilic). The iontophoretic transport of timolol
was decreased by electroporation because the high accumulation of the lipophilic cation
timolol in the s.c. resulted in a decrease of electroosmosis. In contrast, electroosmosis was not
affected by atenolol, and the iontophoretic transport of atenolol was increased by electropo‐
ration. Using two different beta-blockers, the researchers showed that lipophilicity and
positive charges affected the electrotransport of drugs [Escobar-Chávez et al., 2009].
5.1.6. Insulin
The data represented that in vivo, non-invasive insulin delivery to therapeutic levels and
glucose extraction may be achieved by combining electroporation with anionic lipids and
electroosmosis [Escobar-Chávez et al., 2009]. These studies confirmed the synergistic effects
of electroporation (EP) and iontophoresis (IP) on the in vivo percutaneous absorption of human
insulin in rats [Escobar-Chávez et al., 2009].




Selectivity of photodynamic therapy can be improved with localized photosensitizer delivery,
but topical administration is restricted by poor diffusion across the s.c. The researchers used
the electric pulses to increase transdermal transport of D-aminolevulinic acid (ALA), a
protoporphyrin IX (PpIX)-precursor for the photodynamic therapy of superficial skin cancer
and cutaneous metastases of internal malignancies. A two-fold enhancement of PpIX produc‐
tion with electroporative delivery was observed compared to passive delivery. The application
of iontophoresis also increased the ALA permeation by approximately 15-fold [Escobar-
Chávez et al., 2009].
5.1.8. Folic acid antagonists
The topical administration of methotrexate (MTX) for the treatment of psoriasis and neoplastic
diseases is restricted by the poor diffusion of MTX across the s.c. Some studies showed that
electroporation is an efficient method to increase the transdermal transport of MTX. Further‐
more, electroporation of MTX with an anion lipid enhancer under a mild hyperthermic
environment provided a significant transdermal delivery within a short time [Escobar-Chávez
et al., 2009].
5.2. Vaccine delivery
Electroporation-based immunization (especially, EP-mediated DNA vaccine) has been
effective in a number of species including mice, rats, rabbits, non-human primates, pigs and
sheep.
5.2.1. DNA vaccine
DNA immunization has known as an efficient strategy for vaccination [Bolhassani and Rafati,
2009]. The main disadvantage of plasmid DNA vaccines is their poor immunogenicity when
administered as an unformulated intramuscular injection [Anderson and Schneider, 2007]. A
number of approaches for enhancing the potency of DNA vaccines have developed over the
past few years such as: a) Optimization of DNA constructs; b) Development of new DNA
manufacturing processes and formulations; c) Augmentation of immune responses with novel
encoded molecular adjuvants; and d) Improvement of in vivo DNA delivery strategies
including electroporation [Sardesai and Weiner, 2011].
Among them, EP-mediated delivery has generated considerable attention and appeared to
have a great impact in vaccine immunogenicity and efficacy by increasing antigen delivery up
to a 1000 fold versus naked DNA delivery alone [van Drunen Littel-van den Hurk and
Hannaman, 2010; Sardesai and Weiner, 2011]. In many cases, the immune responses and
protection rates observed following DNA administration via EP were comparable or superior
to other vaccine strategies including viral vectors and live/attenuated/inactivated virus
vaccines [Sardesai and Weiner, 2011, Daemi et al., 2012; Hosseinzadeh et al., 2013]. An
electroporation driven plasmid DNA vaccination strategy was studied in animal models for
treatment of prostate cancer. This phPSA plasmid electroporation vaccine strategy could
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effectively activate tumor specific immune responses. Optimization of the approach indicated
that a four-dose regimen provided highest tumor protection. Furthermore, the four-dose
regimen showed optimal and further tumor protection using co-administration of synthetic
oligo CpG. Thus, the in vivo EP-mediated vaccination has potential to be use as a neo-adjuvant
or adjuvant therapy in cancer treatment [Ahmad et al., 2010]. The effect of electroporation on
DNA vaccine potency and gene delivery was studied using skin as a target tissue in larger
animal species such as pig, macaque and sheep. In a macaque model, the higher cellular and
humoral responses were observed to an HIV DNA vaccine harboring IL-12 gene, with
electroporation compared to intradermal DNA injection alone [Hirao et al., 2008]. Further‐
more, the safety and lack of integration after immunization with a high dose of a multigene
HIV-1 vaccine was studied using a combination of the delivery methods jet-injection and
intradermal electroporation. The data showed that plasmids persist in the skin at the site of
injection for at least four months after immunization [Brave, et al., 2010]. The researchers
demonstrated that mice and guinea pigs vaccinated with single-and multi-gene DNA via EP
and then with recombinant gp120 protein (i.e., the synthetic DNA prime-protein boost
protocol) induced significantly higher antibody binding titers [Muthumani et al., 2013].
Recently, Minicircle DNA (a new form of DNA containing only gene expression cassette but
lacking backbone of bacterial plasmid DNA) is a powerful candidate of gene delivery improv‐
ing the levels and the duration of transgene expression in vivo. A novel vaccine delivery system,
including the combined in vivo EP and the minicircle DNA carrying codon-optimized HIV-1
gag gene was prepared to evaluate the immunogenicity of this system. The use of EP delivery
further increased minicircle-based gag gene expression led to the augmentation of humoral
and cellular immune responses. Increased immunogenicity of EP-assisted minicircle-gag may
benefit from increasing local antigen expression, up-regulating inflammatory genes and
recruiting immune cells [Wang et al., 2014]. In sheep, the significantly higher antibody
responses to plasmid-encoded HBsAg were observed after IM delivery followed by electro‐
poration in comparison with conventional IM or ID injection. Importantly, these antibody
responses were sustained for 25 weeks after vaccination [van Drunen Littel-van den Hurk et
al., 2008]. Moreover, various reports have illustrated that cytokine adjuvants have significant
effects on modulating the immune responses to DNA vaccination. Indeed, the co-delivery of
plasmid encoded cytokines is able to quantitatively and qualitatively modulate the immune
responses in a large animal following in vivo electroporation of a DNA vaccine [Yen and
Scheerlinck, 2007]. Although, intra-tumor delivery does not generally result in detectable
serum transgene expression, intramuscular electroporation does result in serum expression.
However, intratumor delivery is more successful than intramuscular delivery in eradicating
primary tumors and in generating systemic immunity. For instance, a number of studies have
demonstrated long-term, complete tumor regression, using delivery of plasmids encoding
IL-12 or IFN-γ as a single agent in melanoma and squamous cell carcinoma (SCC) [Heller and
Heller, 2006]. Complete regression after IL-12 gene therapy in combination with herpes
simplex virus (HSV) thymidine kinase, bleomycin, or recombinant bacillus Calmette-Guérin
(rBCG) has been observed in several experimental models. Electrically mediated bleomycin
delivery combined with IL-2 or granulocyte-macrophage colony-stimulating factor (GM-CSF)
gene therapy also induced long-term complete regression in a small percentage of mice with
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melanomas. Furthermore, complete responses have been observed in a fibrosarcoma model
after delivery of a plasmid encoding GM-CSF and B7.1 [Heller and Heller, 2006]. One of the
main challenges for efficient electroporation in larger animals is to ensure correct match
between the electrical field and the injected DNA. Intramuscular injection of plasmid DNA
followed by electrical stimulation (electroporation) is an efficient method for achieving
therapeutic levels of encoded proteins or eliciting efficient immune responses in smaller
animals such as mice and rats [Tjelle et al., 2006]. Application of short electrical pulses can be
used to enhance gene delivery and DNA vaccination in large animals led to improved cellular
and humoral immune responses. In addition, lowering the electrical field will therefore be
important for reducing electroporation-induced pain. Increasing the number of electrodes
and/or injection volume, could enhance the transfection efficiency of the conventional
electroporation devices [Tjelle et al., 2006]. It will be interesting to electroporate different
plasmids that were mixed together, plasmids mixed with proteins, or mixed proteins to
understand the immune response intensity. It was reported that there is no interference with
two different DNA vaccines, implying that it is possible to co-administrate vaccines directed
against different pathogens at one time [Yuan, 2008; Yuan, 2008]. Induction of a humoral
response against amyloid-β peptide may be beneficial for Alzheimer’s disease (AD) patients.
The potency of an AD DNA epitope vaccine (DepVac) delivered intramuscularly by EP and
intradermally by gene gun (GG) was evaluated for treatment and prevention of AD. The results
indicated that both delivery methods are effective at promoting potent antibodies specific for
Aβ [Davtyan et al., 2012].
Gene delivery into solid tumors after direct injection of formulated or naked DNA preparations
is generally low due to a large number of delivery barriers e.g., tumor complexity. Tumor
electroporation significantly enhanced DNA delivery into solid tumors. Electroporation of
luciferase DNA into mouse and human tumors produced 10-to 1200-fold increases in luciferase
expression compared to tumors injected with luciferase DNA alone [Anwer, 2008]. Tumor
electroporation by six-needle electrodes (100-µs pulses, 1,500 V/cm) produced a 21-fold
enhancement over control while tumor electroporation by caliper electrodes (5,000-µs pulses,
800 V/cm) produced a 42-fold increase. The transfection efficiency of DNA electroporation was
compared with that of non-electroporation methods including, liposome-DNA complexes and
integrin-liposome-DNA complexes in different tumors [Anwer, 2008]. The electroporation
delivery was found to be superior to all other test methods. The maximal enhancement in
transfection efficiency by electroporation was up to 30-fold over naked DNA, 5-to 10-fold over
liposome-DNA complexes, and over 100-fold over integrin-liposome-DNA complexes.
Electroporation produced detectable gene expression in every tumor type while non-electro‐
porated methods were effective only in some tumors [Anwer, 2008]. Moreover, electroporation
enhancement of luciferase transfection was up to 16-fold in mouse skin and up to 83-fold in
pig skin, as compared to that in non-electroporated groups. In another study, the delivery and
anticancer efficacy of MBD2 antisense DNA in electroporated tumors were comparable to the
adenovirus-treated groups [Anwer, 2008].
Intracellular targeting of tumor antigens through its linkage to immunostimulatory molecules
such as calreticulin (CRT) can improve antigen processing and presentation through the MHC
Application of Nanotechnology in Drug Delivery380
class I pathway and increase cytotoxic CD8+T cell production. However, even with these
strategies, the efficacy of such immunotherapeutic strategies is dependent on the identification
of an effective route and method of DNA administration [Best et al., 2009]. Intramuscular
administration of HPV DNA vaccines followed by electroporation increased the number of
antigen-loaded dendritic cells resulting in the enhancement of gene expression. In a compar‐
ison study of the HPV DNA vaccine administered by different methods, electroporation has
been shown to elicit the highest number of E7-specific cytotoxic CD8+T cells and greatest
antitumor immune response compared to intramuscular injection and intradermal gene gun
delivery [Best et al., 2009; Monie et al., 2010]. Generally, electroporation can be considered as
a promising method for delivery of HPV DNA vaccines in human clinical trials [Best et al.,
2009]. For instance, electroporation has been successfully used to administer several HPV DNA
vaccines to mice as well as rhesus macaques, which has prompted its use in an ongoing Phase
I clinical trial of VGX-3100, a vaccine that includes plasmids targeting E6 and E7 proteins of
both HPV subtypes 16 and 18, for treatment of patients with CIN 2 or 3 [Monie et al., 2010].
Regarding to in vivo EP is predominantly carried out intramuscularly, currently, skin EP is
used as an attractive and less invasive option that is able to induce robust adaptive immune
responses. To date, studies of DNA EP in skin have mainly focused on antigen expression,
antigen specific humoral immunity, induction of IFN-γ-producing T cells, and protective
efficacy to infection. Plasmid DNA vaccination using skin electroporation (EP) is a promising
method able to elicit robust humoral and CD8+T-cell immune responses while limiting
invasiveness of delivery [Daemi et al., 2012]. It was shown that subcutaneous administration
of HPV16 E7 DNA linked to C-terminal fragment of gp96 followed by electroporation can
significantly enhance the potency of DNA vaccines [Daemi et al., 2012, Bolhassani et al.,
2011; Bolhassani et al., 2009].
5.2.2. Peptide/ protein vaccine
Larger molecules, including heparin, polylysine, antisense polynucleotides, lactalbumin, and
IgG, have been delivered by transdermal electroporation with proper enhancers. The transport
of calcium-regulating hormones was found to be increased by applying electroporation and
iontophoresis. Anionic lipid formulation has shown significant synergistic effect with electro‐
poration on delivering insulin in vitro and in vivo and has the potential to lower the voltage
threshold to a small level [Hui, 2008]. The reports showed an enhanced transport of human
luteinizing hormone releasing hormone through heat-stripped human epidermis by electro‐
poration. Furthermore, the presence of an ionic surfactant such as sodium dodecyl sulfate
(SDS) reduced the electroporation threshold and significantly improved the transdermal
transport of molecules by electroporation. Indeed, saturated anionic lipids tend to be prefer‐
entially retained in the epidermis during electroporation and result in disrupting the lamellar
structure of the sc lipids, leading to prolonged lifetime of electropores. Using this method, the
transport of both charged and neutral macromolecules was enhanced [Hui, 2008]. Recently,
peptides and mini-gene vaccines are of particular interest since several epitopes of tumor-
associated antigens have been employed as therapeutic and prophylactic cancer vaccines.
Although, small molecular size antigens may be delivered into and through the skin by
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diffusion or by iontophoresis methods, but, higher molecular weight antigens (>1 kDa), such
as peptides, DNA, carbohydrates, as well as vaccine adjuvants need to deliver using an efficient
rout of administration. Needle-free non-adjuvant skin immunization by electroporation has
been reported [Hui, 2008]. For example, delivering the antigenic peptide MYR to mice by
electroporation resulted in mucosal immunity and specific lymph node cell proliferation. Also,
the others indicated that antigen-specific CTL response to the peptide vaccine delivered by
needle-free electroporation/electroosmosis was equivalent to that delivered by intradermal
injection with Freund’s Complete Adjuvant. In this experiment, the Kb-binding OVA peptide
SIINFEKL was used as an example to induce the peptide-specific cytotoxic T lymphocyte (CTL)
response in mice [Hui, 2008; Escobar-Chávez et al., 2009].
Protein-based vaccines have emerged as a potentially promising approach for the generation
of antigen-specific immune responses. However, due to their low immunogenicity, there is a
need for novel approaches to enhance protein-based vaccine potency. One approach to
enhance protein-based vaccine potency is the use of toll-like receptor ligands, such as CpG
oligonucleotides, to activate the antigen-specific T cell immune responses [Kang et al., 2011].
Another approach involves employing a method capable of improving the intramuscularly
delivery of protein-based vaccine led to the slow release of the protein. The studies showed
that intramuscular injection of protein (OVA)-based vaccines in conjunction with CpG
followed by electroporation can significantly enhance the antigen-specific CD8+T cell immune
responses and antitumor effects in vaccinated mice. Similar results were observed using the
HPV-16 E7 protein-based vaccination system [Kang et al., 2011].
5.2.3. RNA-based vaccines
RNA-based vaccines represent an interesting immunization modality, but suffer from poor
stability  and  a  lack  of  efficient  and  clinically  feasible  delivery  technologies.  A  study
evaluated  the  immunogenic  potential  of  naked  in  vitro  transcribed  Semliki  Forest  virus
replicon  RNA  (RREP)  delivered  intradermally  in  combination  with  electroporation
[Johansson et al., 2012]. Replicon-immunized mice showed a strong cellular and humoral
response, compared to mice immunized with regular mRNA. RREP-elicited induction of
interferon-γ secreting CD8+T cells and antibody responses were significantly increased by
electroporation.  The  immune  response  during  the  contraction  phase  was  further  in‐
creased  by  a  booster  immunization,  and  the  proportion  of  effector  memory  cells  in‐
creased significantly. These results demonstrated that naked RREP delivered via intradermal
electroporation can constitute an immunogenic, safe and attractive alternative immuniza‐
tion strategy to DNA-based vaccines [Johansson et al., 2012].
5.2.4. DC-based vaccine
Designing effective strategies to load human dendritic cells (DCs) with tumor antigens is a
challenging approach for DC-based tumor vaccines. In a study, a cytoplasmic expression
system based on mRNA electroporation to efficiently introduce tumor antigens into DCs was
described. Preliminary experiments in K562 cells revealed that mRNA electroporation
compared to plasmid DNA electroporation showed improved transfection efficiency and
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induced a strikingly lower cell toxicity. Next, mRNA electroporation was used for non-viral
transfection of different types of human DCs, including monocyte-derived DCs (Mo-DCs),
CD341 progenitor-derived DCs (34-DCs) and Langerhans cells (34-LCs). High-level transgene
expression by mRNA electroporation was obtained in more than 50% of all DC types [Van
Tendeloo et al., 2001]. In addition, mRNA-electroporated DCs retained their phenotype and
maturational potential. Strikingly, a non-specific stimulation of CTL was observed when DCs
were transfected with plasmid DNA. The data clearly demonstrated that Mo-DCs electropo‐
rated with mRNA efficiently present functional antigenic peptides to cytotoxic T cells.
Therefore, electroporation of mRNA-encoding tumor antigens was a powerful technique to
charge human dendritic cells with tumor antigens and could serve applications in future DC-
based tumor vaccines [Van Tendeloo et al., 2001].
5.3. Gene therapy
Much intensive research has gone into the development of safe and efficient methods for the
delivery of therapeutic genes [Tamura and Sakata, 2003]. Recently, an improved electropora‐
tion protocol was established by optimizing the electroporation parameters including plasmid
concentration, voltage and pulse duration, to deliver DNA into dental follicle cells to study
the roles of candidate genes in regulating tooth eruption [Yao et al., 2009]. Using this approach,
highly efficient gene transfer has already been achieved in muscle and liver as well as in tumors
[Tamura and Sakata, 2003]. Electroporation of mouse muscle with secretory alkaline phospha‐
tase (SEAP) plasmid produced systemic levels of SEAP that were up to 120-fold higher than
those achieved with SEAP plasmid alone. Intramuscular injection of erythropoietin plasmid in
mouse leg produced systemic levels of erythropoietin that were 100-fold higher than those
from erythropoietin plasmid alone. Electroporation of IL-5 plasmid DNA into mouse tibialis
muscle produced 20 ng IL-5/mL while the non-electroporated delivery generated only 0.2 ng
IL-5/mL in the blood. Electroporation of mouse muscle with IL-12 plasmid produced 1500 pg
of IL-12 per injected muscle and 170 pg IL-12/ mL in the blood. The huge improvement in
muscle delivery (up to 10,000-fold over naked DNA) compared with other non-viral gene
delivery systems (10-fold over naked DNA) opens new opportunities for muscle-based gene
therapy [Anwer, 2008].
5.3.1. DNA delivery
Numerous studies on gene transfer have been published in a wide variety of tissues from
animal models [Gehl, 2008]. Most of the studies investigated the treatment of protein defi‐
ciencies and cancers using cytokines. DNA formulations were designed to minimize tissue
damage or enhance expression at weaker electric pulses. These formulations were prepared
with the addition of transfection reagents, membrane permeating agents, tissue matrix
modifiers, targeted ligands, or agents modifying electrical conductivity or membrane stability
to enhance delivery efficiency or reduce tissue damage. These advancements in DNA formu‐
lation could prove to be useful in improving the safety of electroporation protocols for human
applications [Anwer, 2008]. In addition, several DNA formulations have been described for
in vivo gene electroporation. DNA electroporation in saline were shown to enhance transfection
Electroporation – Advantages and Drawbacks for Delivery of Drug, Gene and Vaccine
http://dx.doi.org/10.5772/58376
383
efficiency in several tissues, producing both local and systemic levels of therapeutic proteins.
The enhancement of gene electroporation is associated with significant tissue damage directly
related to electroporation intensity. Milder electroporation conditions, although less toxic, are
transfectionally inefficient. Several formulation strategies have been examined to reduce
electroporation toxicity without affecting transfection activity [Anwer, 2008]. Naked DNA in
saline is the most commonly used formulation for in vivo gene electroporation. In skeletal
muscle, electroporation enhancement of luciferase gene transfer was 10,000-fold over non-
electroporated control. The enhancement of luciferase activity was observed in both small and
large animal species. Histochemical analysis of b-galactosidase plasmid electroporated muscle
showed a larger transfection area per muscle and a higher plasmid copy number per muscle
cell when compared with non-electroporated muscle. Muscle electroporation with FGF1
plasmid also indicated significantly larger transfection area in electroporated muscle as
compared to non-electroporated muscle [Anwer, 2008]. Also, electroporation enhanced intra-
arterial administration of a transgenic construct in rats resulted in expression in mesengial
cells [Stokman et al., 2010]. A report demonstrated the feasibility of electroporating genes into
intact nerve to modify Schwann cell gene expression [Aspalter et al., 2009]. Gene therapy may
represent a promising alternative strategy for cardiac muscle regeneration. In vivo electropo‐
ration with an optimized protocol was also a safe and effective tool for non-viral gene delivery
to the beating heart [Ayuni et al., 2010]. This method was used to examine whether introduction
and expression of PPARγ gene could differentiate skeletal muscle satellite cells to adipocytes
in vivo [Bonamassa and Liu, 2010]. The studies indicated that the cricket (Gryllus bimaculatus)
is a hemimetabolous insect that is emerging as a model organism for the study of neural and
molecular mechanisms of behavioral traits. However, research strategies have been limited by
a lack of genetic manipulation techniques that target the nervous system of the cricket. The
development of a new method for efficient gene delivery into cricket brains was studied using
in vivo electroporation. Plasmid DNA harboring an enhanced green fluorescent protein (EGFP)
gene was injected into adult cricket brains, followed by electroporation at a sufficient voltage.
Expression of EGFP was observed within the brain tissue [Matsumoto et al., 2013]. Gene
therapies for cancer utilizing in vivo electroporation have been proved effective in a number
of experimental murine tumor models. The therapeutic genes delivered in those cases were
diverse including cytokine genes (IL-12) and cytotoxic genes (TRAIL), making a wide range
of therapeutic strategies [Tamura and Sakata, 2003]. Generally, cancer gene therapy has been
studied using in vivo electroporation including suicide genes (e.g., combination of HSV-TK
and prodrug GCV: TK-GCV), apoptosis inducing genes (e.g., TRAIL), immuno-stimulatory
genes (e.g., IFN-gamma, IL-12 and IL-18) and anti-angiogenic genes (e.g., Endostatin) [Tamura
and Sakata, 2003].
5.3.2. Protein delivery
A substantial improvement in muscle delivery with the use of electroporation has renewed
interest in muscle tissue for systemic protein therapy. Several therapeutic proteins have been
expressed from skeletal muscle and secreted into systemic circulation at substantial concen‐
trations with the use of electroporation [Tamura and Sakata, 2003].
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5.3.3. SiRNA delivery
There are increasing interests in physical methods for delivery of siRNA [Oh and Park, 2009].
Among physical methods, electroporation has been frequently studied to stimulate the cellular
and in vivo localized delivery of siRNA by electric pulses [Oh and Park, 2009]. An electropo‐
ration method was established to involve a constant voltage and ‘‘plate and fork’’ type
electrodes and use it for in vivo delivery of siRNA. The electric current correlated to the
microvascular density and vascular endothelial growth factor (VEGF) expression and exhib‐
ited a threshold that assures efficient delivery. VEGF siRNA electroporation suppressed the
growth of tumors exhibiting high VEGF expression to less than 10% of the control level, but it
had no effect on low VEGF-expressing tumors. Notably, a long interval (20 days) of electro‐
poration was enough to obtain a satisfactory effect. Systemically injected siRNA could also be
delivered into tumors by this method [Valero et al., 2008]. In atopic dermatitis mouse model,
the intradermal delivery of cyclooxygenase specific siRNA into the skin by electroporation
resulted in the silencing of the target gene in the skin, and reduced the scratching behavior of
mice [Oh and Park, 2009]. The delivery of tumor necrosis factor α-specific siRNA via electro‐
poration was shown to inhibit inflammation in mice with collagen-induced arthritis. More‐
over, the in vivo silencing of target genes by electrically mediated siRNA delivery was reported
in mice bearing solid tumors [Oh and Park, 2009]. Some studies reported the successful use of
electroporation of siRNA delivery to renal tissue. In rats, injection of siRNA into the renal
artery followed by electroporation led to predominant knockdown of the target protein in the
glomeruli [Stokman et al., 2010]. A number of studies have demonstrated the feasibility of
targeted delivery of oligonucleotides, small interfering RNA (siRNA), plasmid DNA, and viral
vectors to the corneal cells in vivo, specifically stromal keratocytes and corneal epithelial cells,
via intrastromal injection, iontophoresis, electroporation, and gene gun. The combination of
iontophoresis and electroporation was found to be effective in delivering siRNA but not
plasmid DNA into the corneal epithelium [Hao et al., 2010]. Altogether, there is great interest
in platforms which efficiently deliver RNA molecules such as messenger RNA and small
interfering RNA (siRNA) to mammalian tissues [Broderick et al., 2012]. However, the in vivo
delivery of RNA enhanced by EP has not been extensively characterized.
6. Efficient agents involved in electroporation
The type of a nucleic acid and the type of the transfected cell generally affect the efficiency of
electroporation [Stroh et al., 2010]. Skeletal muscle is a preferable target tissue for a number of
reasons including long-term secretion of therapeutic proteins for systemic distribution and
promotion of strong humoral and cellular immune responses post-vaccination. Numerous
factors impact plasmid uptake and expression after intramuscular injection followed by EP.
Briefly, they include: species, targeted muscle, age, plasmid formulation, plasmid concentra‐
tion and dose, pulse pattern, electric field intensity (current, voltage and resistance), pulse
length, lag time, electrode configuration and orientation. These improvements in the condi‐
tions of EP can increase the efficacy of plasmid transfer and lower the total amount of plasmid
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and DNA vaccines required to generate targeted levels of biologically active proteins or
antibodies [Draghia-Akli et al., 2005].
7. Advantages, disadvantages and solutions
The electroporation can be applied equally to all cell types and at all stages of the cell cycle
[Escobar-Chávez et al., 2009]. Collateral damage by electroporation can be serious, compared
with some other physical methods. When electroporation field is applied through the skin
using surface plate electrodes, the major potential drop develops across the skin instead of
across the targeted subcutaneous tissues. Skin edema is a common consequence. Most
electroporation protocols aim to permeate only the plasma membranes. Electroporation of the
nucleus requires a further step, using higher threshold voltage and shorter pulse length
(nucleoporation) [Hui, 2008]. Although the principle of electroporation is applicable to all cell
types, its efficiency depends on the electrical properties of the cells. Smaller cells require higher
field to permeate. This is an important consideration for ex vivo gene delivery especially to
hematopoietic cells. Cells with less conductive contents (such as adipocytes) are less suscep‐
tible. The thresholds for different cells in a heterogeneous tissue would thus vary [Hui, 2008].
DNA formulation with certain types of polymers has been found to enhance electroporation
efficiency and, in some cases, reduce treatment-related toxicity. Anionic polymers, including
poly-L-glutamate, polyacrylic acid, poly-L-aspartate, dextran sulfate, and pectin have been
examined for their ability to enhance electroporation mediated gene transfer in skeletal muscle.
In addition, DNA complexes of cationic liposomes were electroporated into several histolog‐
ically distinct mouse subcutaneous tumors, and the efficiency of gene transfer was compared
with that of naked DNA electroporation [Anwer, 2008, Lai et al., 2008]. Liposomal formulations
were transfectionally superior to naked DNA in B16 melanoma, P22 carcinoma, and SaF
sarcoma but not in T24 human bladder carcinoma or MC2 mammary carcinoma. This variation
in tumor response could be due to differences in the state of tumor necrosis, tumor conduc‐
tivity, or matrix complexity between the different tumors [Anwer, 2008]. A higher interaction
of positively charged lipid-DNA complexes with negatively charged cell surfaces could be one
of the underlying mechanisms in the lipid enhancement of the electroporation. Addition of
anionic liposomes into the electroporation medium has been found to enhance the delivery of
macromolecules into cells. For example, dextran uptake during electroporation was enhanced
by 80-fold with the addition of phosphatidylglycerol and phosphatidylcholine into the
transfection medium. The magnitude of liposome enhancement was dependent on the degree
of lipid saturation but independent of polar head group [Anwer, 2008]. DNA delivery by
electroporation is not target-specific. Several attempts have been made to improve tissue-
specific targeting of electroporated DNA with the use of cell-specific ligands. Antibodies and
other molecular entities that recognize specific cell surface receptors have been conjugated to
delivery vehicles to achieve high cell specificity during electroporation. The technical feasi‐
bility of in vivo DNA targeting by electroporation has not been fully established. For example,
electroporation of integrin conjugated liposome-DNA complexes yields much lower transfec‐
tion efficiency than do the non-targeted systems [Anwer, 2008]. This failure of tumor targeting
Application of Nanotechnology in Drug Delivery386
in vivo could be attributed to poor stability of the targeted complexes in extracellular milieu,
altered integrin receptor affinity for integrin ligand or suboptimal transfection conditions.
Hence, the use of targeted ligands is an attractive approach to improve target specificity of
electroporation, but its in vivo application has not been fully established.
DNA dispersion in muscle is highly restricted because of the rigid collagen-and hyaluronan-
rich matrix surrounding muscle fibers. Pretreatment of tissue with hyaluronidase has been
shown to improve gene delivery into liver and skeletal muscles [Anwer, 2008]. Hyaluroni‐
dase treatment prior to electroporation in skeletal muscle produced a substantial increase
both  in  levels  and  extent  of  gene  transfer  in  skeletal  muscle.  Hyaluronidase  treatment
enhanced transfection efficiency at low electric pulses without significantly damaging the
muscle  structure  or  function.  This  tissue-protective  effect  of  hyaluronidase  has  been
observed  in  ischemic  myocardium  and  tissue  edema.  These  results  demonstrated  that
hyaluronidase  treatment  is  a  useful  approach to  improve  electrogene  transfer  in  higher
species where rigid interstitium is a major limitation to plasmid delivery [Anwer, 2008].
Application of electromigration field (3 V for 30 s) has been shown to enhance the uptake
of DNA-modified gold nanoparticles during cell electroporation. Gold nanoparticles devoid
of DNA coating were not taken up by cells during electroporation. Formulations that can
enhance DNA binding to cell surface in vivo may also enhance electroporation efficiency at
weak electric pulses [Anwer, 2008].
Currently used methods to introduce foreign DNA into mammalian cells are based on bulk
procedures in which large cell numbers are simultaneously transfected, electroporated or
virally infected. All of these methods have a number of specific limitations, such as limited
control over the amount of DNA uptake, the intracellular half-life and fate of the introduced
DNA, and site of genomic integration [Valero et al., 2008]. These limitations represent a serious
drawback in situations where genetically modified stem cells have to be produced for
therapeutic application, including gene therapy and regenerative medicine, especially when
these cells are hard to isolate in large enough numbers. Recently, microfluidic devices have
shown great benefits for studying a variety of cell processes. Of particular importance is the
use of such devices for electroporation, enabling high efficiency transfer of a variety of
macromolecules into cells [Valero et al., 2008]. However, further optimization of DNA vaccine
delivery is needed for this vaccine modality to ultimately be efficacious in humans [Hallengärd
et al., 2012]. The “plate and fork” electrodes were used for the transfer of a plasmid vector for
erythropoietin expression into rat skin and were compared with needle-type and disc-type
electrodes. Therefore, the electroporation conditions for significant efficacy vary with the
molecule to be delivered [Takei et al., 2008].
In general, there are differences in effective variables between a drug and a gene for delivery
by electroporation. High field strength and a short pulse length gave good results, at least with
some of the drugs investigated (e.g., bleomycin), whereas electroporation for genes benefits
from a combination of a low electric field and a long pulse length [Takei et al., 2008].
Membrane poration methods, such as electroporation and sonoporation, are an attractive
alternative in some applications. Indeed, electroporation has demonstrated its efficacy in a
number of DNA and RNA delivery applications for previously difficult-to-transfect primary
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cells.  However,  this method can cause cell  death and has been shown to damage sensi‐
tive materials such as quantum dots,  which aggregate due to exposure to electric fields.
There  have  also  been  limited  reports  of  successful  protein  delivery  by  this  mechanism
[Sharei et al., 2013].
Electroporation is a technique that increases the permeability of cell membranes by changing
the transmembrane potential and subsequently disrupting the lipid bilayer integrity to allow
transportation of molecules across the cell membrane via nano-size pores. This process when
used in a reversible fashion has been used in medicine and research for drug or macromolecule
delivery into cells [Guo et al., 2010; Heish et al., 2011; Phillips et al., 2012; Li et al., 2012; Niessen
et al., 2013; Narayanan et al., 2013]. Irreversible electroporation (IRE) is a new minimally
invasive tumor ablation technique which induces irreversible disruption of cell membrane
integrity by changing the transmembrane potential resulting in cell death. Irreversible
electroporation is currently undergoing clinical investigation as local tumor therapy for
malignant liver and lung lesions [Niessen et al., 2013].
The use of irreversible electroporation (IRE) has been introduced by Rubinsky’s group as a
method to induce irreversible disruption of cell membrane integrity subsequently causing cell
death. IE can effectively create tissue death in micro-to millisecond ranges of treatment time
compared to conventional ablation techniques, which require at least 30 minutes to hours.
Additionally, it is possible to treat a considerably larger lesion with shorter treatment times
than available with current techniques [Guo et al., 2010; Heish et al., 2011; Phillips et al.,
2012; Li et al., 2012; Niessen et al., 2013; Narayanan et al., 2013]. A higher electric voltage leading
to a larger potential gradient to create irreversible electroporation has been studied using in
vitro and in vivo studies. Irreversible electroporation is technically simple to use and suitable
for minimally invasive surgery [Rubinsky, 2007]. Irreversible electroporation is an innovative
local-regional therapy that involves delivery of intense electrical pulses to induce nano-scale
cell membrane defects for tissue ablation. The purpose of this study was to investigate the
feasibility of using irreversible electroporation as a liver-directed ablation technique for the
treatment of hepatocellular carcinoma (HCC) in the N1-S1 rodent model. The findings
suggested that IRE was effective for targeted ablation of liver tumors in the N1-S1 rodent
model; IRE may offer a promising new approach for liver-directed treatment of HCC [Guo et
al., 2010]. The advantage of this technique is that it is drug-free and is targeted [Heish et al.,
2011]. In an experiment, it was shown that direct IRE completely ablated the tumor cells in
osteosarcoma-bearing rats. A significant increase in peripheral lymphocytes, especially
CD3+and CD4+cells, as well as an increased ratio of CD4+/CD8+were detectable after the IE
application. As compared to the surgical resection group, the IRE group exhibited a stronger
cellular immune response. These findings indicated that IRE could not only locally destroy the
tumor but also change the status of cellular immunity in osteosarcoma-bearing rats [Li et al.,
2012]. Some reports indicate that this novel procedure can be used for abdominal cancer
treatment while minimising collateral damage to adjacent tissues because of the unique ability
of the ablation method to target the cell membrane [Phillips et al., 2012]. Irreversible electro‐
poration (IRE) is a new ablative technology that uses high-voltage, low-energy DC current to
create nanopores in the cell membrane, disrupting the homeostasis mechanism and inducing
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cell death by initiating apoptosis in patients with Hepatocellular carcinoma (HCC) [Narayanan
et al., 2013].
8. Clinical trials
One of the methods that improve DNA penetration of the cell is electroporation [Bolhassani
and Rafati, 2011]. EP itself works as an adjuvant to enhance the necessary "danger signals" that
become detectable by the immune system. The tissue damage caused by the application of EP
causes inflammation and recruits DCs, macrophages and lymphocytes to the injection site
inducing significant immune responses, including antibody and T-cell responses [Fioretti et
al., 2014; Saade and Petrovsky, 2012]. In vivo use of electroporation is done by injecting naked
DNA followed by electric pulses from electrodes that are located in situ in the target tissues.
Successful use of electroporation was observed in transfecting muscles, brain, skin, liver, and
tumors. Since every tissue is specific and has its own characteristics, there are no generally
accepted optimal conditions of electroporation that are suitable for effective transfection. These
are dependent both on the amplitude and duration of the electric pulses and on the amount
and concentration of DNA [Bolhassani and Rafati, 2011]. Up to now, several clinical trials have
been planned using the electroporation with DNA vaccines for cancer therapy such as: a) Intra-
tumoral IL-12 DNA plasmid (pDNA) [ID: NCT00323206, phase I clinical trials in patients with
malignant melanoma, Heller and Heller, 2006; Daud et al., 2008]; 2) Intratumoral VCL-IM01
(encoding IL-2) [ID: NCT00223899; phase I clinical trials in patients with metastatic melanoma];
3) Xenogeneic tyrosinase DNA vaccine [ID: NCT00471133, phase I clinical trials in patients
with melanoma]; 4) VGX-3100 [ID: NCT00685412, phase I clinical trials for HPV infections],
and 5) IM injection prostate-specific membrane antigen (PSMA)/ pDOM fusion gene [ID:
UK-112, phase I/II clinical trials for prostate cancer, Low et al., 2009; Fioretti et al., 2010] [Saade
and Petrovsky, 2012; Bolhassani and Rafati, 2011]. Furthermore, Hepatitis C virus DNA
vaccine showed acceptable safety when delivered by Inovio Biomedical's electroporation
delivery system in phase I/II clinical study at Karolinska University Hospital. ChronVac-C is
a therapeutic DNA vaccine being given to individuals already infected with hepatitis C virus
with the aim to clear the infection by boosting a cell-mediated immune response against the
virus. This vaccination was among the first infectious disease DNA vaccine to be delivered in
humans using electroporation based DNA delivery [Bolhassani and Rafati, 2011]. Recent
patents have been focused on the use of genetic immunomodulators, such as “universal” T
helper epitopes derived from tetanus toxin, E. coli heat labile enterotoxin and vegetable
proteins, as well as cytokines, chemokines or co-stimulatory molecules such as IL-6, IL-15,
IL-21 to amplify immunity against cancer. Electroporation-based DNA delivery technology
dramatically enhances cellular uptake of DNA vaccines [Fioretti et al., 2014]. Preliminary data
from an ongoing clinical trial showed electroporation enhanced the frequency and the
magnitude of the anti-HIV-1 T-cell response [Saade and Petrovsky, 2012].
Hemorrhagic fever with renal syndrome (HFRS) is endemic in Asia, Europe and Scandinavia,
and is caused by infection with the hantaviruses Hantaan (HTNV), Seoul (SEOV), Puumala
(PUUV), or Dobrava (DOBV) viruses. The candidate DNA vaccines were developed for HFRS
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expressing Gn and Gc genes of HTNV or PUUV and evaluated in a Phase I study. Three groups
of nine subjects each were vaccinated on days 0, 28 and 56 with the DNA vaccines for HTNV,
PUUV, or mixture of both vaccines using the Ichor Medical Systems TriGrid™ Intramuscular
Delivery System (TDS-IM) [Hooper et al., 2012]. All vaccinations consisted of a total dose of
2.0 mg DNA in an injected volume of 1 mL saline. For the combined vaccine, the mixture
contained equal amounts (1.0 mg) of each DNA vaccine. There were no study-related serious
adverse events (SAEs). Neutralizing antibody responses were detected in 5/9 and 7/9 of
individuals who completed all three vaccinations with the HTNV or PUUV DNA vaccines,
respectively. In the combined vaccine group, 7/9 of the volunteers receiving all three vaccina‐
tions developed neutralizing antibodies to PUUV. The three strongest responders to the PUUV
vaccine also had strong neutralizing antibody responses to HTNV. These results demonstrated
that the HTNV and PUUV DNA vaccines delivered by electroporation separately or as a
mixture are safe. In addition, both vaccines were immunogenic, although when mixed
together, more subjects responded to the PUUV than to the HTNV DNA vaccine [Hooper et
al., 2012]. Figue 2 shows several important EP-mediated DNA vaccines used in clinical trials.
Figure 2. EP-mediated DNA vaccines used in cancer clinical trials
Drug delivery by electroporation has been in experimental use for cancer treatment since 1991
as shown in 11 studies of electrochemotherapy (ECT) of malignant cutaneous or subcutaneous
lesions, e.g., metastases from melanoma, breast or head-and neck cancer. The treatment was
well tolerated and could be performed on an out-patient basis [Gothelf et al., 2003]. At the
Institut Gustave-Roussy, France, the fist clinical trial of ECT with bleomycin in eight patients
with recurrent or progressive head and neck squamous cell carcinoma was published in 1991.
After that, several clinical studies have been performed in different tumors. Clinical trials have
been performed in the treatment of basal cell carcinoma, head and neck cancer (squamous cell
carcinoma, adenocarcinoma and adenoid cystic carcinoma), adenocarcinoma of the breast, and
malignant melanoma. In addition, a case report was published in which metastatic lesions
from a bladder cancer have been successfully treated [Gothelf et al., 2003].
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9. Conclusions
Electroporation is a widely recognized method of gene delivery into mammalian tissues. It is
a highly efficient method, with delivery efficiency better than many non-viral vectors. The
preclinical development of electroporation in vivo is focused on tissues that are easily
accessible to electroporation and can resist to electric pulsation. The standard DNA formula‐
tion for electroporation is DNA in physiological saline. Under optimal conditions, DNA
electroporation in saline yields a 10- to 10,000-fold enhancement in gene delivery efficiency
over non-electroporated controls. This enormous increase in transfection activity, however,
accompanies significant tissue damage and local inflammation, which might not be a disad‐
vantage, if the target is cancer. However, for applications in which expression from normal
tissues is desired, tissue damage and inflammatory response are not favorable to therapeutic
objectives and, therefore, must be minimized. Several formulation strategies have been
designed to enhance electroporation efficiency and minimize toxicity. Hopeful results have
been obtained with some approaches, which must be further developed into clinically viable
formulations for non-cancer applications. Some progresses, such as HIV vaccine, West Nile
virus vaccine have been made; however, these also propose some questions: What are the
differences for best parameters when conduct electroporation on various muscle cells with
distinct morphology and membrane properties that are also different among species? How to
reduce the pain during electroporation? How long can gene expression be maintained after
electrotransfer? Many experiments showed that electroporation is a safe and potent method,
thus electroporation-mediated anticancer gene therapy represents a great therapeutic poten‐
tial. The further improvements of electrodes including shape or arrangement of electrodes and
electric conditions, by which more efficient and reliable gene transfer is achieved, are important
especially in clinical trials. Furthermore, electroporation is an efficient method for enhancing
transdermal drug delivery in vitro and in vivo and expands the range of compounds delivered
transdermally. The combined use of electroporation with other physical enhancers such as
iontophoresis is likely to yield useful and interesting data, to further explore electroporation
as an efficient method of transdermal drug delivery. The technique of electroporation to
enhance anticancer drug (such as bleomycin) delivery to tumor cells, so-called as electroche‐
motherapy, is already being applied clinically against head and neck cancers with little or no
side effects. In summary, electroporation is one of the physicochemical methods for gene and
drug delivery. It is superior in some aspects but also has several drawbacks. Pulse protocol
and electrode design need to be optimized to reduce the main side effects e.g., muscle
contraction.
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